TELA Bio (NASDAQ:TELA – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.
TELA has been the topic of several other research reports. Weiss Ratings raised shares of TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Craig Hallum started coverage on TELA Bio in a research report on Friday, September 25th. They issued a “buy” rating and a $2.00 price objective for the company. Finally, UBS Group set a $2.00 target price on TELA Bio in a research note on Friday, September 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, TELA Bio has a consensus rating of “Moderate Buy” and an average target price of $2.14.
Get Our Latest Research Report on TELA Bio
TELA Bio Price Performance
NASDAQ TELA opened at $0.82 on Friday. The business’s fifty day simple moving average is $1.03 and its 200-day simple moving average is $0.85. The firm has a market cap of $30.18 million, a PE ratio of -1.11 and a beta of 1.46. TELA Bio has a 52 week low of $0.50 and a 52 week high of $1.50.
TELA Bio (NASDAQ:TELA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. TELA Bio had a negative net margin of 53.57% and a negative return on equity of 1,320.81%. The firm had revenue of $18.96 million during the quarter, compared to analyst estimates of $20.00 million. Research analysts expect that TELA Bio will post -0.70 EPS for the current year.
Insider Buying and Selling
In related news, Director Joseph Capper acquired 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the purchase, the director owned 154,827 shares of the company’s stock, valued at $164,116.62. This represents a 47.70% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders acquired 100,000 shares of company stock worth $109,000. Insiders own 1.10% of the company’s stock.
Institutional Trading of TELA Bio
Large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC acquired a new position in shares of TELA Bio during the 2nd quarter worth about $4,420,586. Stonepine Capital Management LLC acquired a new position in TELA Bio in the second quarter valued at $1,996,820. BlackRock Inc. acquired a new stake in TELA Bio during the 2nd quarter worth approximately $281,000. UP Strategic Wealth Investment Advisors LLC purchased a new position in TELA Bio in the 2nd quarter valued at $91,000. Finally, Marshall Wace LLP acquired a new position in shares of TELA Bio during the third quarter worth about $141,000. 94.35% of the stock is currently owned by hedge funds and other institutional investors.
TELA Bio Company Profile
TELA Bio is a medical technology company that develops and markets products for soft-tissue reconstruction. Its portfolio includes OviTex Reinforced Tissue Matrices, which combine biologic materials derived from ovine (sheep) tissue with polymer reinforcement. The products are designed to support tissue repair and are used in procedures including hernia and abdominal wall reconstruction. The company also offers products for plastic and reconstructive surgery, including OviTex PRS, and other solutions for soft-tissue repair.
See Also
- Five stocks we like better than TELA Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
